The Proline 7 Substitution in the Preproneuropeptide Y Is Associated with Higher Hepatic Lipase Activity In Vivo

Hepatic lipase (HL) functions as a lipolytic enzyme that hydrolyzes triglycerides and phospholipids present in circulating plasma lipoproteins. Plasma HL activity is known to be regulated by hormonal and metabolic factors, but HL responsiveness to insulin as well as its role in modulating atherosclerotic risk is still controversial. We investigated on the influence of a known polymorphism in the neurotransmitter neuropeptide Y (NPY) on HL activity in two different cohorts consisting of diabetic and nondiabetic patients. HL activity was 24% and 34% higher on nondiabetic and diabetic subjects in the presence of the 7Pro allele in NPY, respectively. The presence of the 7Pro allele was an independent predictor of HL activity in multivariate analyses in both cohorts. These data suggest a regulatory effect of NPY on HL activity. Among carriers of the 7Pro allele, we also found a statistically significant lower absolute number of infarctions compared to noncarriers (p < 0.05) and a nonsignificant trend towards less myocardial infarction in the 7Pro allele diabetic carriers (p = 0.085). In conclusion, the common 7Pro allele in NPY was associated with higher HL activity in nondiabetic and diabetic subjects and its presence seems to coincide with a lower frequency of certain cardiovascular events.

[1]  Tetsuya Nakamura,et al.  Prazosin-stimulated release of hepatic triacylglyceride lipase from primary cultured rat hepatocytes is involved in the regulation of cAMP-dependent protein kinase through activation of the Ca^2+/calmodulin-dependent protein kinase-II , 2016, Pharmacological reports : PR.

[2]  D. Burks,et al.  Hepatic lipase inactivation decreases atherosclerosis in insulin resistance by reducing LIGHT/Lymphotoxin β-Receptor pathway , 2016, Thrombosis and Haemostasis.

[3]  H. Mabuchi,et al.  Hepatic Lipase: a Comprehensive View of its Role on Plasma Lipid and Lipoprotein Metabolism. , 2015, Journal of atherosclerosis and thrombosis.

[4]  G. Ferns,et al.  Association of neuropeptide Y gene rs16147 polymorphism with metabolic syndrome in patients with documented coronary artery disease , 2015, Annals of human biology.

[5]  G. Ferns,et al.  Neuropeptide Y Leu7Pro Polymorphism Associated With the Metabolic Syndrome and Its Features in Patients With Coronary Artery Disease , 2013, Angiology.

[6]  G. López,et al.  Hepatic lipase activity is increased in non‐alcoholic fatty liver disease beyond insulin resistance , 2012, Diabetes/metabolism research and reviews.

[7]  G. Ferns,et al.  High frequency of Neuropeptide Y Leu7Pro polymorphism in an Iranian population and its association with coronary artery disease. , 2012, Gene.

[8]  T. Lehtimäki,et al.  Neuropeptide Y signal peptide Pro7 substitution protects against coronary artery atherosclerosis: the Helsinki Sudden Death Study. , 2008, Atherosclerosis.

[9]  Y. Kesäniemi,et al.  Leu7Pro polymorphism of PreproNPY associated with an increased risk for type II diabetes in middle-aged subjects , 2007, European Journal of Clinical Nutrition.

[10]  C. Cavadas,et al.  Deletion of the neuropeptide Y (NPY) Y1 receptor gene reveals a regulatory role of NPY on catecholamine synthesis and secretion , 2006, Proceedings of the National Academy of Sciences.

[11]  A. Verhoeven,et al.  Sterol-regulatory-element binding protein inhibits upstream stimulatory factor-stimulated hepatic lipase gene expression. , 2005, Atherosclerosis.

[12]  W. März,et al.  Association analysis of the polymorphism T1128C in the signal peptide of neuropeptide Y in a Swedish hypertensive population. , 2004, Journal of hypertension.

[13]  G. Lewis,et al.  Hepatic lipase mRNA, protein, and plasma enzyme activity is increased in the insulin-resistant, fructose-fed Syrian golden hamster and is partially normalized by the insulin sensitizer rosiglitazone. , 2004, Diabetes.

[14]  H. Jansen.  Hepatic lipase: Friend or foe and under what circumstances? , 2004, Current atherosclerosis reports.

[15]  M. Doolittle,et al.  Maturation of Hepatic Lipase , 2004, Journal of Biological Chemistry.

[16]  M. Koulu,et al.  Leucine 7 to proline 7 polymorphism in the preproneuropeptide Y is associated with proteinuria, coronary heart disease, and glycemic control in type 1 diabetic patients. , 2004, Diabetes care.

[17]  G. Crepaldi,et al.  Relevance of hepatic lipase to the metabolism of triacylglycerol-rich lipoproteins. , 2003, Biochemical Society transactions.

[18]  M. Koulu,et al.  Enhanced endothelium-dependent vasodilation in subjects with Proline7 substitution in the signal peptide of neuropeptide Y. , 2003, Atherosclerosis.

[19]  Lijun Li,et al.  Neuropeptide Y: a new mediator linking sympathetic nerves, blood vessels and immune system? , 2003, Canadian journal of physiology and pharmacology.

[20]  L. Martinez,et al.  Hepatic lipase: structure/function relationship, synthesis, and regulation. , 2002, Journal of lipid research.

[21]  M. Laakso,et al.  Association of leucine 7 to proline 7 polymorphism in the preproneuropeptide Y with serum lipids in patients with coronary heart disease. , 2002, Molecular genetics and metabolism.

[22]  M. Koulu,et al.  Enhanced exercise-induced GH secretion in subjects with Pro7 substitution in the prepro-NPY. , 2001, The Journal of clinical endocrinology and metabolism.

[23]  M. Koulu,et al.  Leucine7 to proline7 polymorphism in the preproneuropeptide Y is associated with the progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish men. , 2001, Atherosclerosis.

[24]  M. Koulu,et al.  Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans1 , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  Makoto Sato,et al.  Neuropeptide Y in central control of feeding and interactions with orexin and leptin , 2001, Endocrine.

[26]  L. Niskanen,et al.  Leucine 7 to proline 7 polymorphism in the neuropeptide Y gene is associated with enhanced carotid atherosclerosis in elderly patients with type 2 diabetes and control subjects. , 2000, The Journal of clinical endocrinology and metabolism.

[27]  R. F. Hoyt,et al.  In vivo evidence for both lipolytic and nonlipolytic function of hepatic lipase in the metabolism of HDL. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[28]  S. Grundy,et al.  Hepatic lipase: new insights from genetic and metabolic studies. , 1999, Current opinion in lipidology.

[29]  L. Niskanen,et al.  Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels , 1998, Nature Medicine.

[30]  A. Verhoeven,et al.  Maturation and secretion of rat hepatic lipase is inhibited by alpha1B-adrenergic stimulation through changes in Ca2+ homoeostasis: thapsigargin and EGTA both mimic the effect of adrenaline. , 1998, The Biochemical journal.

[31]  Z. Żukowska-Grójec.  Neuropeptide Y , 1995, Annals of the New York Academy of Sciences.

[32]  M. Taskinen,et al.  Normalization of Lipoprotein Composition by Intraperitoneal Insulin in IDDM: Role of increased hepatic lipase activity , 1994, Diabetes Care.

[33]  J. Hokanson,et al.  Effect of hepatic lipase on LDL in normal men and those with coronary artery disease. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[34]  D. Johnston,et al.  The Role of Insulin Insensitivity and Hepatic Lipase in the Dyslipidaemia of Type 2 Diabetes , 1991, Diabetic medicine : a journal of the British Diabetic Association.

[35]  R. Davis,et al.  Synthesis of hepatic lipase in liver and extrahepatic tissues. , 1987, Journal of lipid research.

[36]  M. Laakso,et al.  Relationship between postheparin plasma lipases and high-density lipoprotein cholesterol in different types of diabetes , 1987, Diabetologia.

[37]  J. Brunzell,et al.  Human adipose tissue lipoprotein lipase: changes with feeding and relation to postheparin plasma enzyme. , 1985, The American journal of physiology.

[38]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[39]  L. Bouter,et al.  Neuropeptide Y polymorphism significantly magnifies diabetes and cardiovascular disease risk in obesity: the Hoorn Study , 2009, European Journal of Clinical Nutrition.

[40]  A. Verhoeven,et al.  Acute effects of adrenaline on hepatic lipase secretion by rat hepatocytes. , 1997, Metabolism: clinical and experimental.

[41]  R. Jackson,et al.  Regulation of hepatic lipase expression by an intermediate of the cellular cholesterol biosynthetic pathway. , 1991, Advances in experimental medicine and biology.